• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Kogenate FS
    / Bayer

    Active Ingredient

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    1 x 500 IU

    partial basket chart 13841 11210, 11234


    1 x 1,000 IU

    partial basket chart 13840 11233, 11211

    Related information


    See prescribing information for full details.


    Treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor FVIII.



    Known intolerance or allergic reactions to constituents of the preparation. Known hypersensitivity to mouse or hamster protein may be contraindicated.

    Special Precautions

    FVIII deficiency should be proven prior to therapy. Patients treated with any AHF preparation should be carefully monitored for the development of antibodies to FVIII by appropriate clinical observation and laboratory tests. Pregnancy and lactation: Should be used during pregnancy and lactation only if clearly indicated.

    Side Effects

    Local injection site reactions, dizziness, rash.
    See prescribing information for full details.


    Drug interactions

    See prescribing information for full details.

    Bayer Healthcare LLC
    Licence holder